Full-Life technologies limited ("Full-Life") is a fully integrated global Nuclear Health company headquartered in Shanghai with operations in Europe. We seek to own the entire value chain for radio-ligand production, research, development and commercialization in order to deliver clinical impact for patients. Our core platform seeks to attack the two core issues that exist in radiopharmaceuticals today: 1) the ability to produce in high quality and quantity radioisotope to meeting tomorrow's needs and 2) innovative translational and biology research platform targeting the radio-pharma treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with demonstrated track record in life-science company building as well as radio-isotope research and clinical development. We seek to unleash the power of half-life in order to bring the potential of a Full-Life to patients across the world.